Efficacy and Safety of Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: Results From a Pivotal Open-label Study With a Median Follow-up of ≥2 Years

Journal:
Journal of the American Academy of Dermatology
Published:
DOI:
10.1016/j.jaad.2025.09.009
Affiliations:
29
Authors:
23
Go to article
Institutions Authors Share
Checkpoint Therapeutics, United States of America (USA)
3.000000
 0.13
University of Wollongong (UOW), Australia
2.000000
 0.09
Immunology and New Concepts in Immunotherapy (INCIT), France
1.000000
 0.04
Cancer Research Center of Lyon (CRCL), France
1.000000
 0.04
Hospital Universitario Virgen Macarena, Spain
1.000000
 0.04
Vall d'Hebron University Hospital (HUVH), ICS, Spain
1.000000
 0.04
Unité Mixte de Recherche RIGHT, France
1.000000
 0.04
Phoenix Pharma, South Africa
1.000000
 0.04
Brigham and Women's Hospital (BWH), United States of America (USA)
1.000000
 0.04
Institute of Biomedical Research in Malaga (IBIMA), Spain
1.000000
 0.04
St Andrew's Hospital, France
1.000000
 0.04
Pindara Private Hospital, Australia
1.000000
 0.04
Instituto Valenciano de Oncologia (IVO), Spain
1.000000
 0.04
Wilgers Oncology Center, South Africa
1.000000
 0.04
Gallipoli Medical Research Foundation, Australia
0.833333
 0.04
Greenslopes Private Hospital, Australia
0.833333
 0.04
University of the Sunshine Coast (USC), Australia
0.500000
 0.02
Sunshine Coast Haematology and Oncology Clinic (SCHOC), Australia
0.500000
 0.02
Christchurch Hospital, New Zealand
0.500000
 0.02
Canterbury District Health Board (CDHB), New Zealand
0.500000
 0.02
Alps Grenoble University Hospital (CHU Grenoble Alpes), France
0.500000
 0.02
Grenoble Alpes University (UGA), France
0.500000
 0.02
CHU Nice, France
0.500000
 0.02
Université Côte d'Azur (UniCA), France
0.500000
 0.02
Princess Alexandra Hospital, Australia
0.333333
 0.01
Interested in Clinical Sciences?